<VariationArchive RecordType="classified" VariationID="6413" VariationName="NM_003060.2:c.33_1427del" VariationType="Deletion" Accession="VCV000006413" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-12-17" DateCreated="2018-09-29" MostRecentSubmission="2018-09-29">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="21452" VariationID="6413">
      <GeneList>
        <Gene Symbol="SLC22A5" FullName="solute carrier family 22 member 5" GeneID="6584" HGNC_ID="HGNC:10969" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>5q31.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="132369710" stop="132395612" display_start="132369710" display_stop="132395612" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="131705400" stop="131731305" display_start="131705400" display_stop="131731305" Strand="+" />
          </Location>
          <OMIM>603377</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_003060.2:c.33_1427del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>5q31.1</CytogeneticLocation>
      </Location>
      <OtherNameList>
        <Name>G12_L477del</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003060.4" sequenceAccession="NM_003060" sequenceVersion="4" change="c.34_1428del" MANESelect="true">
            <Expression>NM_003060.4:c.34_1428del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="603377.0005" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">Deletion beginning in exon 1 and ending in exon 8 of gene SLC22A5, resulting in a predicted 92-aa truncated polypeptide.</Comment>
      <Comment DataSource="NCBI curation" Type="GenomicLocationNotEstablished">NCBI staff reviewed the paper by Lamhonwah and Tein, 1998 (PubMed 9826541), cited in this submission.  The deletions were characterized only in cDNA.</Comment>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff reviewed the sequence information reported in PubMed 9826541 Fig. 3 to determine the location of this allele on the current reference sequence. </Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003060.2:c.33_1427del AND Renal carnitine transport defect" Accession="RCV000006782" Version="5">
        <ClassifiedConditionList TraitSetID="1778">
          <ClassifiedCondition DB="MedGen" ID="C0342788">Renal carnitine transport defect</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1998-11-18" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1998-11-18" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2018-09-29" MostRecentSubmission="2018-09-29">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">2235122</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9826541</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1778" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1316" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Primary carnitine deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine uptake defect</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine deficiency, systemic, due to defect in renal reabsorption of carnitine</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine plasma-membrane transporter deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Renal carnitine transport defect</ElementValue>
                <XRef ID="Renal+carnitine+transport+defect/9212" DB="Genetic Alliance" />
                <XRef ID="21764004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine Deficiency, Systemic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine transporter deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE TRANSPORTER, PLASMA-MEMBRANE, DEFICIENCY OF</ElementValue>
                <XRef Type="MIM" ID="212140" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Systemic primary carnitine deficiency disease</ElementValue>
                <XRef ID="MONDO:0008919" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CDSP</ElementValue>
                <XRef Type="MIM" ID="212140" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">SCD</ElementValue>
                <XRef Type="MIM" ID="212140" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CUD</ElementValue>
                <XRef Type="MIM" ID="212140" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Systemic primary carnitine deficiency (CDSP) is a disorder of the carnitine cycle that results in defective fatty acid oxidation. It encompasses a broad clinical spectrum including the following: Metabolic decompensation in infancy typically presenting between age three months and two years with episodes of hypoketotic hypoglycemia, poor feeding, irritability, lethargy, hepatomegaly, elevated liver transaminases, and hyperammonemia triggered by fasting or common illnesses such as upper respiratory tract infection or gastroenteritis. Childhood myopathy involving heart and skeletal muscle with onset between age two and four years. Pregnancy-related decreased stamina or exacerbation of cardiac arrhythmia. Fatigability in adulthood. Absence of symptoms. The latter two categories often include mothers diagnosed with CDSP after newborn screening has identified low carnitine levels in their infants.</Attribute>
                <XRef ID="NBK84551" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5104" />
                <XRef ID="5104" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">22420015</ID>
                <ID Source="BookShelf">NBK84551</ID>
              </Citation>
              <XRef ID="158" DB="Orphanet" />
              <XRef ID="C0342788" DB="MedGen" />
              <XRef ID="MONDO:0008919" DB="MONDO" />
              <XRef Type="MIM" ID="212140" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="26978" SubmissionDate="2018-09-26" DateLastUpdated="2018-09-29" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603377.0005_CARNITINE DEFICIENCY, SYSTEMIC PRIMARY" title="SLC22A5, 1394-BP DEL_CARNITINE DEFICIENCY, SYSTEMIC PRIMARY" />
        <ClinVarAccession Accession="SCV000026978" DateUpdated="2018-09-29" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1998-11-18">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 2 patients with carnitine uptake defect (CDSP; 212140) reported by Tein et al. (1990), Lamhonwah and Tein (1998) found compound heterozygosity for mutations in the SLC22A5 gene. Both patients showed a partial cDNA deletion of nucleotides 255-1649, resulting in a predicted truncated protein of 92 amino acids. In patient 1, the second mutant allele carried a 19-bp insertion between nucleotides 874 and 875, resulting in a frameshift and yielding a predicted truncated protein of 284 amino acids (603377.0006); in patient 2, the second mutant allele had a deletion of nucleotides 875-1046, resulting in a predicted truncated protein of 237 amino acids (603377.0008). Patient 1 was a male of Italian descent; patient 2 was a female of Mexican descent with a family history of an affected brother who had died of cardiomyopathy. Both children had early-onset myopathy, cardiomyopathy, and failure to thrive with less than 5% of control carnitine concentrations in muscle and had a dramatic improvement in growth, strength, and cardiac function following institution of high dose oral carnitine supplementation. Patient 1 had a striking decrease in renal reabsorption of carnitine (52%; normal greater than 95%) despite low serum carnitine concentrations. His muscle carnitine concentration increased to only 13% of control after carnitine supplementation; however, this was sufficient to result in a resolution of the lipid storage and a restoration of motor power.</Attribute>
              <Citation>
                <ID Source="PubMed">2235122</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9826541</ID>
              </Citation>
              <XRef DB="OMIM" ID="212140" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC22A5" />
          </GeneList>
          <Name>SLC22A5, 1394-BP DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1394-BP DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603377.0005" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CARNITINE DEFICIENCY, SYSTEMIC PRIMARY</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="26978" TraitType="Disease" MappingType="Name" MappingValue="CARNITINE DEFICIENCY, SYSTEMIC PRIMARY" MappingRef="Preferred">
        <MedGen CUI="C0342788" Name="Renal carnitine transport defect" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>